Refining treatment approaches in early-stage lung cancer
Refining treatment approaches in early-stage lung canc
Innovative treatment approaches: non–EGFR-directed bispecific antibodies and ADCs
Innovative treatment approaches: non–EGFR-directed bis
HER2 aberrations and other oncogenic drivers
HER2 aberrations and other oncogenic drivers HER2 mu
Concurrent MET/EGFR inhibition and third-generation EGFR TKIs
Concurrent MET/EGFR inhibition and third-generat
Preface – WCLC 2024
Preface – WCLC 2024 Professor Benjamin Solomon MBB
Proposals for the 9th edition of the TNM classification
Proposals for the 9th edition of the TNM classif
MARS 2: no benefit of decortication in early-stage malignant mesothelioma
MARS 2: no benefit of decortication in early-stage mal
Trop-2–directed ADCs in conjunction with immunotherapy: EVOKE-02 and TROPION-Lung04
Trop-2–directed ADCs in conjunction with immunot
Refining first-line regimens for extensive-stage small-cell lung cancer
Refining first-line regimens for extensive-stage
Improved anti-EGFR strategies and other targeted innovations
Improved anti-EGFR strategies and other targeted
